Giovanni F.M. Strippoli

TL;DR: The benefits and harms of immunosuppression for the treatment of IgAN are determined including mortality, infection, hospitalisation, ESKD requiring renal replacement therapy (dialysis or kidney transplantation), doubling of serum creatinine, remission of proteinuria, and end of treatment urinary protein excretion, serum creat inine, and glomerular filtration rate.

TL;DR: Antiplatelet treatment protects fistula from thrombosis or loss of patency, but has little or no effect on graft patency and uncertain effects on vascular access maturation for dialysis and major bleeding.

TL;DR: In this article, the benefits and harms of phosphate binders for people with chronic kidney disease (CKD) with particular reference to relevant biochemical endpoints, musculoskeletal and cardiovascular morbidity, hospitalisation, and death were assessed.

TL;DR: There are no indications for IgG in the prophylaxis of CMV disease in recipients of solid organ transplants, and the efficacy of older agents (immunoglobulins, anti CMV vaccines and interferon) are examined.

TL;DR: Based on generally poor quality trials, the use of neutral-pH peritoneal dialysates with reduced GDPs resulted in greater urine volumes and residual renal function after 12 months, but without other clinical benefits.